Citius Oncology, Inc.

NASDAQ:CTOR

Drug Manufacturers - General

Healthcare
$0.56 +4.23%

+$0.03 today

Market cap
$51.83M
Beta
3.42
P/E (TTM)
-1.6
EPS (TTM)
-$0.42
52W Low $0.49High $6.19

Volume 0.15M

Average 0.12M

CTOR Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

Citius Oncology, Inc.NASDAQ: CTOR

Gross Margin · Q2 FY2026 · quarter ended Mar 2026

Gross margin at 80.3%

Gross margin was 80.3% in Q2 FY2026. On a trailing-twelve-month basis it was 80.1%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
80.3%+0.3 pp QoQ
Last fiscal yearSep 2025
—— YoY
LTMMar 2026
80.1%— YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3 years———
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

No Gross Margin data reported for this period type.

Gross Margin vs competitors

How CTOR compares with its peers on the latest reported figures

  • CTOR's LTM Mar 2026 gross margin of 80.1% is the 2nd highest of the 7 companies compared; the peer median is 48.1%.
CTOR Competitors Peer median
Gross Margin for CTOR and competitors
Company Period LTM level YoY 3-year change
SPROSpero Therapeutics, Inc.LTM Mar 2026100.0% +296.0 pp+0.0 pp
CTORCitius Oncology, Inc.LTM Mar 202680.1% ——
SCLXScilex Holding CompanyLTM Mar 202655.0% -17.0 pp-21.9 pp
OWLTOwlet, Inc.LTM Mar 202650.9% -1.4 pp+17.0 pp
LNSRLENSAR, Inc.LTM Mar 202645.3% -2.1 pp-10.0 pp
MCRBSeres Therapeutics, Inc.LTM Mar 2026-20.9% ——
FATEFate Therapeutics, Inc.LTM Mar 2026-415.8% +126.5 pp-179.8 pp
FBRXForte Biosciences, Inc.FY2025— ——
VORVor Biopharma Inc.FY2025— ——
ACTUActuate Therapeutics IncFY2025— ——
Peer median (excluding CTOR) 48.1%-1.4 pp-10.0 pp

Competitors are the stored peer set for CTOR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2022
Sep 2022
FY2023
Sep 2023
FY2024
Sep 2024
FY2025
Sep 2025
Revenue0000
Cost of Revenue0000
Gross Profit0000
Gross Margin————
Research & Development6.86M4.24M4.93M6.42M
Selling, General & Admin2.86M7.88M15.65M17.1M
Operating Expenses9.71M12.12M20.57M23.52M
Depreciation & Amortization9.71M000
EBITDA0(12.12M)(20.57M)(23.49M)
EBITDA Margin————
Operating Income(9.71M)(12.12M)(20.57M)(23.52M)
Operating Margin————
Interest Income00036.37K
Interest Expense000218.03K
Other Income / Expenses000(181.66K)
Income Before Tax(9.71M)(12.12M)(20.57M)(23.7M)
Pre-Tax Margin————
Income Tax Expense1.15M576K576K1.06M
Net Income(10.87M)(12.7M)(21.15M)(24.76M)
Net Margin————
EPS (Basic)(0.08)(0.19)(0.30)(0.34)
EPS (Diluted)(0.08)(0.19)(0.30)(0.34)
Weighted Avg Shares90.16M89.48M71.55M73.27M
Weighted Avg Shares (Diluted)90.16M89.48M71.55M73.27M

Citius Oncology, Inc.

NASDAQ:CTOR

Intrinsic Alpha fair value

Locked

Current Price

$0.56

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.